Ananda Developments

Directors

Shareholders

Announcements

Publications

Broker Coverage

Company and Advisors

Corporate Governance

Home

Updates

Investment Opportunity

Ubuntu

Ananda Developments plc (AQSE: ANA) is pleased to announce that two of its patent pending cannabinoid medicines, MRX2 and MRX2T, will be used in two NHS-funded Phase IIIa epilepsy clinical trials involving up to 500 patients in total. The trials will be run by investigators at University College London and Great Ormond Street Hospital, and are due to start during 2025.

The objective of the trials test the safety and efficacy of Ananda’s specific cannabidiol (CBD) and CBD plus tetrahydrocannabinol (THC) formulations for two treatment-resistant epilepsy groups in children and adults. If the results are favourable, they will pave the way for a submission of these medicines to the MHRA and other regulatory bodies for regulatory approval.

The trials are being funded by a partnership between NHS England and National Institute for Health and Care Research (NIHR) and will be co-led by Professor Finbar O’Callaghan and Professor Helen Cross of University College London (UCL) and Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH).